Table 2.
Extreme group analyses: poor compliers versus good compliers with quality of life assessment
| Poor compliers n=20 | Good compliers n=18 | P | |
|---|---|---|---|
| Age | |||
| Mean | 64.3 | 60.9 | 0.03 |
| Range | 36-88 | 48-73 | |
| Gender | |||
| Female | 9 | 5 | NS |
| Male | 11 | 13 | |
| Cancer stage | |||
| I (pT1-2 NO MO) | 3 | 8 | |
| II (pT3-4 NO MO) | 6 | 3 | 0.04 |
| III (all pT N+ MO) | 4 | 6 | |
| IV (all pT/N M+) | 7 | 1 | |
| ASA grade | |||
| I | 2 | - | |
| II | 5 | 12 | 0.05* |
| III | 5 | 5 | |
| IV | 3 | - | |
| No ASA classification | 5 | 1 | |
| Surgical therapy | |||
| None | - | - | NS |
| Low anterior resection | 13 | 10 | |
| Rectal extirpation | 7 | 8 | |
| Other | - | - | |
| Postoperative adjuvant therapy | |||
| Yes | 8 | 5 | |
| No | 12 | 13 | |
| Intention of primary treatment | |||
| Curative | 14 | 17 | 0.05 |
| Palliative | 6 | 1 | |
| Tumour progression | 13 | 5 | 0.022 |
| After curative primary treatment | |||
| local recurrence | 4 | 2 | |
| Distant metastases | 3 | 3 | |
| After palliative primary treatment | |||
| General progression | 6 | - | |
| Therapeutic interventions | 7 | 1 | 0.026 |
| Resection of metastases/local recurrence | 2 | 1 | |
| Palliative chemotherapy | 5 | 00 | |
| Death | 9 | 0 | 0.001 |
| Mean survival (months) | 18.6 | 24.0 | 0.001 |
ASA=American Society of Anesthesiologists; NS=not significant
*
Pearson's χ2 test for low-risk patients (ASA I+II) versus high-risk patients (ASA III+IV)